WHAT IS CLAIMED IS:

1. Use of a therapeutically effective amount of a peptide having an amino acid sequence consisting of:

$$(R^1)_x\text{-}P\text{-}(R^2)_y,$$

wherein:

P is an amino acid sequence having at least 90% identity to a sequence ~~85% identity to at least nine consecutive amino acids~~ of SEQ ID NO:344;

R^1 is an amino acid sequence consisting of from 1 to 80 amino acids;

R^2 is an amino acid sequence consisting of from 1 to 80 amino acids; and

each of x and y are independently zero or one

in the manufacture of a medicament for inducing an immune tolerance to FVIII in a subject in need thereof, wherein said subject i) is being treated with FVIII therapy or ii) is being treated with an immune tolerance induction therapy.

~~2. The use of claim 1, wherein P is an amino acid sequence having at least 85% identity to a sequence of at least nine consecutive amino acids of SEQ ID NO:344.~~

~~3. The use of claim 1, wherein P is an amino acid sequence having at least 90% identity to a sequence of at least nine consecutive amino acids of SEQ ID NO:344.~~

42. The use of claim 1, wherein P is an amino acid sequence having at least 95% identity to a sequence ~~of at least nine consecutive amino acids~~ of SEQ ID NO:344.

~~5~~3. The use of claim 1, wherein P is an amino acid sequence identical to a sequence ~~of at least nine consecutive amino acids~~ of SEQ ID NO:344.

64. The use according to any one of claims 1 to 53, wherein x and y are both zero.

75. The use according to any one of claims 1 to 53, wherein x is one and y is zero.

86. The use according to any one of claims 1 to 53, wherein x is zero and y is one.

~~97~~. The use according to any one of claims 1 to ~~53~~, wherein x and y are both one.

~~108~~. The use according to any one of claims 1 to ~~53~~, wherein the peptide consists of from 9 to 100 amino acids.

~~119~~. The use of claim ~~108~~, wherein the peptide consists of from 9 to 50 amino acids.

~~1210~~. The use of claim ~~108~~, wherein the peptide consists of from 9 to 25 amino acids.

~~1311~~. The use according to any one of claims 1 to ~~1210~~, wherein the medicament is for

administering with a therapeutically effective amount of a second peptide having an amino acid sequence consisting of:

$$(R^1)_x\text{-P-}(R^2)_y,$$

wherein:

P is an amino acid sequence having at least 85% identity to at least nine consecutive amino acids of a sequence selected from SEQ ID NOS: 10, 68, 159, 250, 344, 477, 568, 659, and 740;

R^1 is an amino acid sequence consisting of from 1 to 80 amino acids;

R^2 is an amino acid sequence consisting of from 1 to 80 amino acids; and

each of x and y are independently zero or one.

~~1412~~. The use according to any one of claims 1 to ~~1311~~, wherein the development of anti-FVIII antibodies is prevented in the subject.

~~1513~~. The use according to any one of claims 1 to ~~1311~~, wherein the medicament reduces an amount of anti-FVIII antibodies present in the subject.

~~1614~~. A peptide consisting of the amino acid sequence:

$$(R^1)_x\text{-P-}(R^2)_y,$$

wherein:

P is an amino acid sequence having at least 90% identity to a sequence ~~85% identity to at least nine consecutive amino acids~~ of SEQ ID NO:344;

R^1 is an amino acid sequence consisting of from 1 to 80 amino acids;

R^2 is an amino acid sequence consisting of from 1 to 80 amino acids; and

each of x and y are independently zero or one.

~~17. The peptide of claim 16, wherein P is an amino acid sequence having at least 85% identity to a sequence of at least nine consecutive amino acids of SEQ ID NO:344.~~

~~18. The peptide of claim 16, wherein P is an amino acid sequence having at least 90% identity to a sequence of at least nine consecutive amino acids of SEQ ID NO:344.~~

~~19~~15. The peptide of claim ~~16~~14, wherein P is an amino acid sequence having at least 95% identity to a sequence of ~~at least nine consecutive amino acids of~~ SEQ ID NO:344.

~~20~~16. The peptide of claim ~~16~~14, wherein P is an amino acid sequence identical to a sequence of ~~at least nine consecutive amino acids of~~ SEQ ID NO:344.

~~21~~17. The peptide according to any one of claims ~~16~~14 to ~~20~~16, wherein x and y are both zero.

~~22~~18. The peptide according to any one of claims ~~16~~14 to ~~20~~16, wherein x is one and y is zero.

~~23~~19. The peptide according to any one of claims ~~16~~14 to ~~20~~16, wherein x is zero and y is one.

~~24~~20. The peptide according to any one of claims ~~16~~14 to ~~20~~16, wherein x and y are both one.

~~25~~21. The peptide according to any one of claims ~~16~~14 to ~~20~~16, wherein the peptide consists of from 9 to 100 amino acids.

~~26~~22. The peptide of claim ~~25~~21, wherein the peptide consists of from 9 to 50 amino acids.

~~27~~23. The peptide of claim ~~25~~21, wherein the peptide consists of from 9 to 25 amino acids.

~~28~~24. A composition comprising a peptide according to any one of claims ~~16~~14 to ~~27~~23.

~~29~~25. The composition of claim ~~28~~24, wherein the composition is formulated for pharmaceutical administration.

~~30~~26. The composition of claim ~~28~~24 or ~~29~~25, wherein the composition further comprises a second polypeptide, the second polypeptide consisting of the amino acid sequence:

$$(R^1)_x\text{-}P\text{-}(R^2)_y,$$

wherein:

P is an amino acid sequence having at least 85% identity to at least nine consecutive amino acids of a sequence selected from SEQ ID NOS: 10, 68, 159, 250, 344, 477, 568, 659, and 740;

R^1 is an amino acid sequence consisting of from 1 to 80 amino acids;

R^2 is an amino acid sequence consisting of from 1 to 80 amino acids; and

each of x and y are independently zero or one.

~~31~~27. A method of making a FVIII peptide, the method comprising the steps of:

a) providing a culture of cells comprising a polynucleotide that encodes a FVIII peptide according to any one of claims ~~16~~14 to ~~27~~23; and

b) expressing the peptide in the culture of cells.

~~32. A method of identifying a FVIII pepti de-specific T cell, the method comprising:~~

~~a) combining a plurality of $CD4^+$ T cells with a peptide complexed with a MHC class II multimer, wherein the peptide is a FVIII peptide according to any one of claims 16 to 27; and~~

~~b) identifying at least one of the members of the plurality of $CD4^+$ T cells that is specific for the peptide complexed with the MHC class II multimer.~~

~~33. The method of claim 32, wherein the MHC class II multimer is a MHC class II tetramer.~~

~~34. The method of claim 32 or 33, wherein the peptide or MHC class II multimer further comprises a detectable moiety.~~

~~35. The method according to any one of claims 32 to 34, further comprising isolating the at least one $CD4^+$ T cell that is specific for the peptide.~~

~~36. The method of claim 35, wherein the $CD4^+$ T cell is isolated using flow cytometry.~~

~~37~~28. A fusion protein comprising:

a Factor VIII peptide according to any one of claims ~~16~~14 to ~~27~~23; and a second peptide.

~~38~~29. The fusion protein of claim ~~37~~28, wherein the second peptide is a reporter peptide.

~~39~~30. The fusion protein of claim ~~37~~28 or ~~38~~29, wherein the fusion protein is encoded by a nucleic acid.

~~40~~31. The fusion protein of claim ~~37~~28 or ~~38~~29, wherein the FVIII peptide is chemically linked to the second peptide.